Weishu Wu, Xiaotian Tan, Jennifer Zupancic, John S Schardt, Alec A Desai, Matthew D Smith, Jie Zhang, Liangzhi Xie, Maung Khaing Oo, Peter M Tessier and 1 more
Article in Analytical chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Weishu WuDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.
Xiaotian TanDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0001-5529-8092
Jennifer ZupancicDepartment of Chemical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.
John S SchardtDepartment of Chemical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.
Alec A DesaiDepartment of Chemical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.
Matthew D SmithDepartment of Chemical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.
Jie ZhangBeijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing 100176, China.
Liangzhi XieBeijing Key Laboratory of Monoclonal Antibody Research and Development, Sino Biological Inc., Beijing 100176, China.
Maung Khaing OoOptofluidic Bioassay, LLC, Ann Arbor, Michigan 48103, United States.
Peter M TessierDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-3220-007X
Xudong FanDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0003-0149-1326
Funding
Design and Evolution of Polyvalent Domain Antibodies Specific for Tau AggregatesRF1AG059723 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KANE, RAVI S., TESSIER, PETER M · 2018 to 2022
$2.4M
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregatesR35GM136300 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TESSIER, PETER M · 2020 to 2024
$1.5M
Administrative Supplement: Activity-based Discovery and OptimizationF32GM137513 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHARDT, JOHN SAMUEL · 2020 to 2022
Neutralizing monoclonal antibodies and nanobodies have shown promising results as potential therapeutic agents for COVID-19. Identifying such antibodies and nanobodies requires evaluating the neutralization activity of a large number of lead molecules
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Rapid and Quantitative · full record | OpenQuestion